Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

1(25%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Detailed Status

Completed3

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed375%

recruiting125%

Recent Activity

1 active trials

Showing 4 of 4

recruitingphase_1

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

NCT03686124

completedphase_1

Clinical Trials (4)

Showing 4 of 4 trials

NCT03686124Phase 1

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Recruiting

NCT03247309Phase 1

TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)

Completed

NCT03441100Phase 1

TCR-engineered T Cells in Solid Tumors: IMA202-101

Completed

NCT02876510Phase 1

ACTolog in Patients With Solid Cancers

Completed

All 4 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 4